Invion Limited (ASX:IVX)

Australia flag Australia · Delayed Price · Currency is AUD
0.0430
+0.0020 (4.88%)
Jun 19, 2026, 3:07 PM AEST
Market Cap3.98M -46.5%
Revenue (ttm)n/a
Net Income-10.50M
EPS-0.13
Shares Out 96.97M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4
Open0.0430
Previous Close0.0410
Day's Range0.0430 - 0.0430
52-Week Range0.0350 - 0.2000
Beta0.44
Analystsn/a
Price Target1.85 (+4,202.33%)
Earnings DateAug 28, 2026

About Invion

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical... [Read more]

Sector Healthcare
Founded 2000
Employees 4
Stock Exchange Australian Securities Exchange
Ticker Symbol IVX
Full Company Profile

Financial Performance

Financial Statements